Amicus Therapeutics Long Term Debt

Amicus Therapeutics (FOLD) currently reports a long-term debt of $430M as of December 2025. That compares with $440M in the prior-year period — down 0.4% year over year. Use the charts on this page to explore Amicus Therapeutics's long-term debt history and peer comparisons.

Amicus Therapeutics's long-term debt decreased from $440M to $430M — a 0.4% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Amicus Therapeutics reported $430M in long-term debt as of December 2025. That compares with $440M in the prior-year period — down 0.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $430M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Amicus Therapeutics, and consider following FOLD for alerts when major investors trade the stock.

Amicus Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $430M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FOLD with unrelated industries.